This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Relief from local symptoms of prostatic carcinoma and from metastases in soft tissues or in bone has been afforded by castration, administration of estrogens or a combination of the two methods of therapy. The results are shown, not only by symptomatic improvement, but by x-ray evidence of regression of metastases and by reduction of the acid phosphatase content of blood. The latter is a product of prostatic tissue metabolism. To date there is reason to question the really curative value of these types of therapy, but palliation is of value even though it may not do more than prolong life and comfort for several months. It is probable that the use of estrogenic materials for this purpose is safe. The benefits are recognized only in cases of carcinoma arising in prostatic tissue. Accordingly, the Council has adopted the following paragraph for insertion in the New and Nonofficial Remedies section "Overies":
THE USE OF ESTROGENS IN THE TREATMENT OF PROSTATIC CARCINOMA. JAMA. 1943;123(7):417. doi:10.1001/jama.1943.82840420010009a
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: